Clinical trial
Open access
Sep 2026
Cadonilimab plus lenvatinib in advanced endometrial cancer: the multicenter single-arm phase II CLEAR-EC trial
Treatment options are limited for women with advanced endometrial cancer after platinum-based chemotherapy. In this single-arm, multicenter phase II CLEAR-EC trial with a safety run-in, we evaluated cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, plus lenvatinib as second-line or later therapy (ClinicalTr...
Lin Zhou, Jing Zhao, Si-Jian Li et al.
· Nature Communications · 0 citations